Tau is a microtubule-associated protein that becomes hyperphosphorylated and aggregates into neurofibrillary tangles in Alzheimer's disease and related tauopathies. Tau pathology correlates more directly with cognitive decline than amyloid burden does, which has kept tau-targeted programs on the pipeline map even as amyloid-directed antibodies (lecanemab, donanemab) reached the market. The tau modality landscape in 2026 spans three main approaches: antisense oligonucleotides (ASOs) that reduce MAPT RNA and thus tau production at the source, AAV gene therapies that use RNA-interference or antisense payloads with sustained expression, and monoclonal antibodies that target extracellular tau fragments.
The AAIC 2026 tau data (July 12-15 London) sharpened the competitive picture. Biogen's Phase 2 CELIA study of diranersen (BIIB080), an intrathecally administered anti-MAPT ASO, is the first tau-targeting therapy to show both pathology reduction and cognitive benefit in early Alzheimer's disease; the program now advances toward Phase 3 development. Voyager Therapeutics reported 3-month GLP NHP toxicology data for VY1706, a blood-brain-barrier-crossing AAV gene therapy targeting tau, showing 64% tau reduction after a single IV dose at 13 weeks and FDA IND clearance ahead of H2 2026 first-in-human dosing. Denali's DNL628 uses the Oligonucleotide TransportVehicle platform to deliver an anti-MAPT ASO across the BBB via transferrin-receptor shuttling, with data expected 1H 2027.
Stories here cover tau-targeted clinical programs and the shifting evidence base. See [[alzheimers-disease]] and [[antisense-oligonucleotide]] for adjacent threads.
Biogen (NASDAQ: BIIB) presented full Phase 2 CELIA study data for diranersen (BIIB080), an investigational tau-targeting antisense oligonucleotide (ASO) delivered intrathecally, at AAIC 2026 in London on Tuesday July 14, 2026 during the Developing Topics in Phase 2 Clinical Trials Session (2:00-3:30 PM BST). The 76-week placebo-controlled study evaluated three doses (60 mg every 24 weeks, 115 mg every 24 weeks, and 115 mg every 12 weeks) and did not meet its primary endpoint of dose response on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at Week 76. Strong reductions in tau pathology occurred across all studied doses, generally consistent with the Phase 1b study. Prespecified analyses of cognitive endpoints demonstrated slowing of clinical decline across all doses, with the effect particularly pronounced at the lowest 60 mg q24w dose. Biogen framed the results as the first randomized Phase 2 evidence of a tau-directed therapy showing both biomarker impact and cognitive benefit, and plans to advance diranersen to registrational Phase 3 development.
Voyager Therapeutics (NASDAQ: VYGR) presented six-month Good Laboratory Practice (GLP) toxicology data for VY1706, its investigational blood-brain-barrier-crossing AAV gene therapy targeting tau for Alzheimer's disease, in a Developing Topics late-breaking poster at AAIC 2026 in London on Monday July 13, 2026. The updated six-month data extends the prior three-month timepoint (64% reduction reported earlier this month): a single intravenous dose delivered sustained tau protein reduction up to 75% in key brain regions of non-human primates over six months. VY1706 was well tolerated with no adverse clinical pathology and no histopathological findings up to the highest dose tested. Notably, the program showed none of the typical AAV liver transaminase elevations at any dose level throughout six months, plasma neurofilament levels remained generally stable with no dose-related increases, and there were no cellular immune activations. Voyager received FDA Investigational New Drug (IND) clearance for VY1706, enabling initiation of a clinical trial in adults with early Alzheimer's disease with dosing expected in the second half of 2026.
Eisai announced Monday July 13, 2026 that its investigational anti-microtubule-binding region (MTBR) tau antibody etalanetug (development code E2814) reduced levels of plasma extracellular MTBR-tau243 (eMTBR-tau243), a novel fluid biomarker of Alzheimer's disease tau tangle pathology, in findings presented during a Featured Research Session at AAIC 2026 in London. Etalanetug reduced plasma eMTBR-tau243 by 78% at 3 months and by more than 90% at 9 months. The biomarker was largely absent in healthy adults and detected only in patients with dominantly inherited Alzheimer's disease (DIAD), suggesting it reflects disease-related tau pathology at the pathological source (neurofibrillary tangle formation) rather than tau physiology broadly. eMTBR-tau243 consists of tau fragments that include amino acid residue 243 and MTBR sequences, arising during the formation of neurofibrillary tangles, and can now be measured with a blood test to track tau pathology non-invasively. Etalanetug is Eisai's second-generation Alzheimer's antibody program beyond lecanemab (LEQEMBI, amyloid protofibril-directed), extending the company's franchise from amyloid to tau.
Voyager Therapeutics (NASDAQ: VYGR) presented Developing Topics late-breaking poster data at AAIC 2026 in London (July 12-15) featuring VY1706, its investigational blood-brain-barrier-crossing AAV gene therapy targeting intracellular and extracellular tau for Alzheimer's disease. The 3-month GLP non-human primate toxicology study showed VY1706 was well tolerated at a single intravenous dose up to the highest level tested (5E13 vg/kg), with no adverse clinical pathology or histopathological findings. Tau protein was reduced up to 64% in key brain regions of non-human primates at 13 weeks following a single IV dose. Voyager received FDA Investigational New Drug (IND) clearance for VY1706 in H1 2026, enabling initiation of a clinical trial in adults with early Alzheimer's disease with dosing expected in the second half of 2026. The program extends the same BBB-delivery-plus-tau-reduction thesis that Denali's DNL628 OTV pursues via anti-tau ASO; both address the same therapeutic hypothesis through different modalities (AAV gene therapy vs. anti-sense oligonucleotide).
Biogen (NASDAQ: BIIB) will present Phase 2 CELIA study data for diranersen (BIIB080), an investigational tau-targeting antisense oligonucleotide (ASO), at AAIC 2026 in London during the Developing Topics in Phase 2 Clinical Trials session on Tuesday July 14, 2:00–3:30 PM BST. The 18-month CELIA study evaluated diranersen in patients with early Alzheimer's disease and is the first study to show reduction in tau pathology and cognitive benefit for a tau-targeted therapy. Biogen will present clinical, biomarker, and safety data that build on the May 2026 topline announcement and further characterize the molecule as the program advances toward Phase 3 development. Diranersen targets MAPT RNA to reduce tau production at its source, a differentiated approach to addressing abnormal tau both inside and outside neurons. The CELIA readout is a peptide-adjacent nucleic-acid biologic milestone that shifts the tau treatment conversation from 'reducing pathology' to 'reducing pathology and moving cognition.'
A 2026 review published in Cell and Tissue Research (Springer Nature) synthesized the current understanding of brain peptides in Alzheimer's disease pathophysiology and therapeutic development. The review's central organizing distinction is between pathogenic peptide species (amyloid-β oligomers, tau-derived fragments) that drive neuronal dysfunction and endogenous neuropeptides that exert neuroprotective effects: neuropeptide Y (NPY), vasoactive intestinal peptide (VIP), and pituitary adenylate cyclase-activating peptide (PACAP) are the three best-characterized protective classes. Adjacent April 2026 IJMS review covers the same neuropeptide neuroprotection thesis with broader Parkinson's-disease applicability. Advances in peptide chemistry are enabling two distinct therapeutic strategies: aggregation inhibitors that prevent amyloid-β oligomerization, and receptor-selective neuropeptide analogues that recapitulate endogenous NPY/VIP/PACAP signaling with improved blood-brain-barrier penetration. The peptide-neurodegeneration thread runs parallel to the BioArctic-Lilly $800 million BrainTransporter pact (June 23, peptide-delivery focus), Insilico-SK Biopharm $2.5B AI-neuroimmune deal (June 22 BIO 2026 opening), and the NVG-291 PTPσ inhibitor that NervGen is preparing for Phase 3 in chronic SCI mid-2026.